From inherited to sporadic AD—crossing the biomarker bridge
Authors:
- 25 September 2012
- journal article
- research article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 8 (11) , 598-600
Abstract
Whether dominantly inherited variants of Alzheimer disease (AD) and 'sporadic' forms exhibit similar pathophysiological and biomarker signatures remains unresolved. A landmark study has proposed a biomarker progression model of dominantly inherited AD, but a complex systems biology and physiology approach is required to translate these findings to sporadic disease.Keywords
This publication has 8 references indexed in Scilit:
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian KnotAlzheimer's & Dementia, 2012
- US government sets out Alzheimer’s planNature, 2012
- The role of genetics for biomarker development in neurodegenerationProgress in Neurobiology, 2011
- Advances and perspectives from genetic research: development of biological markers in Alzheimer’s diseaseExpert Review of Molecular Diagnostics, 2010
- Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectivesNature Reviews Drug Discovery, 2010
- Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseNature Reviews Neurology, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010